The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.
Gonadotropin-releasing hormone/analogs and derivatives
Hospitals
Hydroxymethylglutaryl-CoA reductase inhibitors
Prostatic neoplasms
Veterans
Journal
Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
27
07
2018
revised:
09
11
2018
accepted:
19
11
2018
pubmed:
12
12
2018
medline:
4
9
2019
entrez:
12
12
2018
Statut:
ppublish
Résumé
Statins are thought to possess antineoplastic properties related to their effect on cell proliferation and steroidogenesis. Progression to castrate resistant prostate cancer (CaP) includes de-regulation of androgen synthesis suggesting a role for statins in this setting. Our goal was to assess the role of statin use on oncologic outcomes in patients with advanced CaP being treated with androgen deprivation therapy (ADT). The national VA database was used to identify all men diagnosed with CaP who were treated with ADT for at least 6 months between 2000 and 2008 with follow-up through May 2016. Our cohort was stratified based on statin use of at least 6 months duration during the same time. Multivariable Cox proportional hazards analyses with inverse propensity score weighted (IPSW) adjustment were calculated to assess for primary outcomes of CaP-specific survival (CSS), overall survival (OS) and skeletal related events (SREs). A total of 87,346 patients on ADT were included in the study cohort, 53,360 patients used statins and 33,986 did not. Statin users were younger in age (median 73 vs. 76, P < 0.001), more likely to have a higher Charlson comorbidity index (CCI) >3 (3.1% vs. 2.5%, P < 0.001) and more likely to have a high grade (Gleason score 8-10) cancer (12.3% vs. 10.9%, P < 0.001). Statin users had longer OS (median 6.5 vs. 4.0 years P < 0.001) and decreased death from CaP (5-year CSS 94.0% vs. 87.3%, P < 0.001). Statin use was also associated with longer time to a SRE (median 5.9 vs. 3.7 years, P < 0.001). On multivariable Cox proportional hazards analysis with inverse propensity score weighted, statin use was an independent predictor of improved OS (hazard ratio [HR] 0.66, confidence interval [CI] 0.63-0.68; P < 0.001), CSS (HR 0.56, 95% CI 0.53-0.60; P < 0.001), and SREs (HR 0.64, 95%CI 0.59-0.71; P < 0.001) when controlling for age, race, Charlson comorbidity index, prostate-specific antigen, and Gleason score. The use of statins in men on ADT for CaP is associated with improved CSS and OS. Statins are inexpensive, well-tolerated medications that offer a promising adjunct to ADT, but require further prospective studies.
Sections du résumé
BACKGROUND
Statins are thought to possess antineoplastic properties related to their effect on cell proliferation and steroidogenesis. Progression to castrate resistant prostate cancer (CaP) includes de-regulation of androgen synthesis suggesting a role for statins in this setting. Our goal was to assess the role of statin use on oncologic outcomes in patients with advanced CaP being treated with androgen deprivation therapy (ADT).
METHODS
The national VA database was used to identify all men diagnosed with CaP who were treated with ADT for at least 6 months between 2000 and 2008 with follow-up through May 2016. Our cohort was stratified based on statin use of at least 6 months duration during the same time. Multivariable Cox proportional hazards analyses with inverse propensity score weighted (IPSW) adjustment were calculated to assess for primary outcomes of CaP-specific survival (CSS), overall survival (OS) and skeletal related events (SREs).
RESULTS
A total of 87,346 patients on ADT were included in the study cohort, 53,360 patients used statins and 33,986 did not. Statin users were younger in age (median 73 vs. 76, P < 0.001), more likely to have a higher Charlson comorbidity index (CCI) >3 (3.1% vs. 2.5%, P < 0.001) and more likely to have a high grade (Gleason score 8-10) cancer (12.3% vs. 10.9%, P < 0.001). Statin users had longer OS (median 6.5 vs. 4.0 years P < 0.001) and decreased death from CaP (5-year CSS 94.0% vs. 87.3%, P < 0.001). Statin use was also associated with longer time to a SRE (median 5.9 vs. 3.7 years, P < 0.001). On multivariable Cox proportional hazards analysis with inverse propensity score weighted, statin use was an independent predictor of improved OS (hazard ratio [HR] 0.66, confidence interval [CI] 0.63-0.68; P < 0.001), CSS (HR 0.56, 95% CI 0.53-0.60; P < 0.001), and SREs (HR 0.64, 95%CI 0.59-0.71; P < 0.001) when controlling for age, race, Charlson comorbidity index, prostate-specific antigen, and Gleason score.
CONCLUSION
The use of statins in men on ADT for CaP is associated with improved CSS and OS. Statins are inexpensive, well-tolerated medications that offer a promising adjunct to ADT, but require further prospective studies.
Identifiants
pubmed: 30528885
pii: S1078-1439(18)30465-4
doi: 10.1016/j.urolonc.2018.11.017
pmc: PMC6919968
mid: NIHMS1051536
pii:
doi:
Substances chimiques
Androgen Antagonists
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Observational Study
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
130-137Subventions
Organisme : NIDDK NIH HHS
ID : T35 DK062709
Pays : United States
Informations de copyright
Copyright © 2018. Published by Elsevier Inc.
Références
J Natl Cancer Inst. 2011 Jun 8;103(11):885-92
pubmed: 21498780
Urol Oncol. 2017 Mar;35(3):123
pubmed: 28159490
Ann Transl Med Epidemiol. 2014;1(1):null
pubmed: 25621309
Prostate. 2017 Mar;77(4):337-349
pubmed: 27862098
Lipids Health Dis. 2014 Mar 26;13:56
pubmed: 24666612
J Urol. 2010 Aug;184(2):494-9
pubmed: 20620405
Stat Med. 2008 Nov 29;27(27):5709-24
pubmed: 18712779
Nurs Adm Q. 2015 Oct-Dec;39(4):311-8
pubmed: 26340242
Cancer Res. 2008 Aug 1;68(15):6407-15
pubmed: 18676866
J Clin Oncol. 2014 Jan 1;32(1):5-11
pubmed: 24190110
N Engl J Med. 2012 Nov 8;367(19):1792-802
pubmed: 23134381
PLoS One. 2012;7(10):e46691
pubmed: 23049713
J Hematol Oncol. 2015 Nov 13;8:128
pubmed: 26566796
BMC Med Res Methodol. 2015 Aug 19;15:65
pubmed: 26286392
J Clin Oncol. 2017 Oct 10;35(29):3290-3297
pubmed: 28806117
Urology. 1985 Mar;25(3):223-7
pubmed: 3976112
BJU Int. 2013 Mar;111(3 Pt B):E71-7
pubmed: 23017100
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s
pubmed: 17062708
Curr Opin Pharmacol. 2012 Dec;12(6):751-9
pubmed: 22824430
J Urol. 2011 Apr;185(4):1268-73
pubmed: 21334020
Medicine (Baltimore). 2015 Sep;94(39):e1644
pubmed: 26426656
Prostate. 2011 Feb 15;71(3):298-304
pubmed: 20717902
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607